2588 related articles for article (PubMed ID: 1989645)
21. Negative regulators of in vivo erythropoiesis: interaction of IL-1 alpha and TNF-alpha and the lack of a strict requirement for T or NK cells for their activity.
Johnson CS; Pourbohloul SC; Furmanski P
Exp Hematol; 1991 Feb; 19(2):101-5. PubMed ID: 1991491
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody.
Pietersz GA; Toohey B; McKenzie IF
J Drug Target; 1998; 5(2):109-20. PubMed ID: 9588867
[TBL] [Abstract][Full Text] [Related]
23. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
24. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor beta increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle.
Belizario JE; Dinarello CA
Cancer Res; 1991 May; 51(9):2379-85. PubMed ID: 2015601
[TBL] [Abstract][Full Text] [Related]
26. Augmentation by IL-1 alpha of tumor necrosis factor-alpha cytotoxicity in cells transfected with adenovirus E1A.
Tsuji Y; Ninomiya-Tsuji J; Torti SV; Torti FM
J Immunol; 1993 Mar; 150(5):1897-907. PubMed ID: 8436824
[TBL] [Abstract][Full Text] [Related]
27. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
Morimoto H; Yonehara S; Bonavida B
Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
[TBL] [Abstract][Full Text] [Related]
28. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII).
Wu PC; Alexander HR; Huang J; Hwu P; Gnant M; Berger AC; Turner E; Wilson O; Libutti SK
Cancer Res; 1999 Jan; 59(1):205-12. PubMed ID: 9892208
[TBL] [Abstract][Full Text] [Related]
29. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia.
Watanabe N; Niitsu Y; Umeno H; Sone H; Neda H; Yamauchi N; Maeda M; Urushizaki I
Cancer Res; 1988 Feb; 48(3):650-3. PubMed ID: 3335027
[TBL] [Abstract][Full Text] [Related]
30. Cellular and cytokine dependent monocyte-mediated leukemic cell death: modulation by interferon-gamma and tumor necrosis factor-alpha.
van de Loosdrecht AA; Beelen RH; Ossenkoppele GJ; Broekhoven MG; Langenhuijsen MM
Exp Hematol; 1993 Mar; 21(3):461-8. PubMed ID: 8440344
[TBL] [Abstract][Full Text] [Related]
31. Poly ADP-ribosylation of a 90-kDa protein is involved in TNF-alpha-mediated cytotoxicity.
Agarwal S; Piesco NP
J Immunol; 1994 Jul; 153(2):473-81. PubMed ID: 8021488
[TBL] [Abstract][Full Text] [Related]
32. Human TNF mutants with selective activity on the p55 receptor.
Van Ostade X; Vandenabeele P; Everaerdt B; Loetscher H; Gentz R; Brockhaus M; Lesslauer W; Tavernier J; Brouckaert P; Fiers W
Nature; 1993 Jan; 361(6409):266-9. PubMed ID: 8380906
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
[TBL] [Abstract][Full Text] [Related]
34. Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.
Bialas T; Kolitz J; Levi E; Polivka A; Oez S; Miller G; Welte K
Cancer Res; 1988 Feb; 48(4):891-8. PubMed ID: 3257413
[TBL] [Abstract][Full Text] [Related]
35. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
Wagley Y; Yoo YC; Seo HG; Rhee MH; Kim TH; Kang KW; Nah SY; Oh JW
Biochem Biophys Res Commun; 2007 Mar; 354(4):985-91. PubMed ID: 17274948
[TBL] [Abstract][Full Text] [Related]
36. Effects of recombinant murine tumor necrosis factor-alpha on immune function.
Gordon C; Wofsy D
J Immunol; 1990 Mar; 144(5):1753-8. PubMed ID: 2307839
[TBL] [Abstract][Full Text] [Related]
37. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.
Sheehan KC; Ruddle NH; Schreiber RD
J Immunol; 1989 Jun; 142(11):3884-93. PubMed ID: 2469726
[TBL] [Abstract][Full Text] [Related]
38. Direct evidence for an intracellular role for tumor necrosis factor-alpha 1. Microinjection of tumor necrosis factor kills target cells.
Smith MR; Munger WE; Kung HF; Takacs L; Durum SK
J Immunol; 1990 Jan; 144(1):162-9. PubMed ID: 2153163
[TBL] [Abstract][Full Text] [Related]
39. Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones.
Pagliacci MC; Fumi G; Migliorati G; Grignani F; Riccardi C; Nicoletti I
Lymphokine Cytokine Res; 1993 Dec; 12(6):439-47. PubMed ID: 8123760
[TBL] [Abstract][Full Text] [Related]
40. The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
Eisenthal A; Rosenberg SA
J Immunol; 1989 Apr; 142(7):2307-13. PubMed ID: 2647849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
